IP Library Granted Patent US 11,267,790
Granted Patent B2
US 11,267,790 · App. 16/922,080 · Granted Mar 8, 2022

Processes for preparing plasma kallikrein inhibitors

Inventors: Sukanto Sinha (San Francisco, CA); Tamie Chilcote (San Francisco, CA); Baburaj Krishnan (Bangalore, IN); Ganapati Bhat (Bangalore, IN); Vineet Malik (Bangalore, IN)
Assignees: Rezolute, Inc.; ActiveSite Pharmaceuticals, Inc.
C07D231/14C07D207/34C07D249/04C07D277/56C07D307/68C07D333/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,267,790
App. No.
16/922,080
Granted
Mar 8, 2022
Kind
B2
Abstract

A process for preparing and purifying a compound of Formula I is provided: or a salt thereof, wherein the subscript m is an integer of from 0 to 3; each R a is independently selected from the group consisting of (C 3 -C 8 )cycloalkyl, (C 1 -C 4 )haloalkyl, halogen, —OH, —OR 1 , —SH, —SR 1 , —S(O)R 1 , —S(O) 2 R 1 , —SO 2 NH 2 , —C(O)NH 2 , —C(O)NHR 1 , —C(O)N(R 1 ) 2 , —C(O)R 1 , —C(O)H, —CO 2 R 1 , —NO 2 , —NH 2 , —NHR 1 , —N(R 1 ) 2 , wherein each R 1 is independently (C 1 -C 8 )alkyl; L is a linking group selected from the group consisting of a bond or CH 2 ; Q a , Q b , and Q c are each members independently selected from the group consisting of N, S, O and C(R q ) wherein each R q is independently selected from the group consisting of H, C 1-8 alkyl, halo and phenyl, and the ring having Q a , Q b , Q c and Y as ring vertices is a five-membered ring having two double bonds; and Y is selected from the group consisting of C and N.

Claims (31)

1. A process for preparing a compound of Formula I

or a salt thereof,

wherein the subscript m is an integer of from 0 to 3;

each R a is independently selected from the group consisting of (C 3 -C 8 )cycloalkyl, (C 1 -C 4 )haloalkyl, halogen, —OH, —OR 1 , —SH, —SR 1 , —S(O)R 1 , —S(O) 2 R 1 , —SO 2 NH 2 , —C(O)NH 2 , —C(O)NHR 1 , —C(O)N(R 1 ) 2 , —C(O)R 1 , —C(O)H, —CO 2 H, —CO 2 R 1 , —NO 2 , —NH 2 , —NHR 1 , —N(R 1 ) 2 , wherein each R 1 is independently (C 1 -C 8 )alkyl;

L is a linking group selected from the group consisting of a bond or CH 2 ;

Q a Q b , and Q c are each members independently selected from the group consisting of N, S, O and C(R q ) wherein each R q is independently selected from the group consisting of H, C 1-8 alkyl, halo and phenyl, and the ring having Q a , Q b , Q c and Y as ring vertices is a five-membered ring having two double bonds; and

Y is selected from the group consisting of C and N;

the method comprising:

(a) subjecting a compound of Formula II to reducing conditions, to provide the compound of Formula I as a crude product, wherein the compound of Formula II is:

2. The process of claim 1 , wherein the reducing conditions comprise Raney nickel and H 2 .

3. The process of claim 2 , wherein the reducing conditions comprise Raney nickel at about 10 to about 40 mol %, and H 2 at about 2 to about 20 kg/cm 3 .

4. The process of claim 3 , wherein the reducing conditions comprise Raney nickel at about 20 mol %, and H 2 at about 10 kg/cm 3 .

5. The process of claim 1 , wherein the reducing conditions further comprise acetic acid as a solvent, and heating at a temperature of about 30° C. to about 70° C.

6. The process of claim 2 , further comprising:

(b) forming a slurry of the crude product in water at a temperature of about 25° C. to about 70° C. to provide a nickel-depleted product.

7. The process of claim 6 , further comprising:

(c) heating the nickel-depleted product in a solvent to remove further nickel.

8. The process of claim 7 , wherein the solvent comprises a mixture of ethanol and acetic acid.

9. The process of claim 7 , wherein the solvent comprises a mixture of methanol, dimethyl glyoxime, and methyl-t-butyl ether.

10. The process of claim 1 , wherein the compound of Formula II is obtained by combining a compound of Formula III with hydroxylamine or a salt thereof under basic conditions, wherein the compound of Formula III is:

to provide the compound of Formula II.

11. The process of claim 10 , wherein the basic conditions comprise triethylamine and ethanol.

12. The process of claim 11 , wherein the basic conditions further comprise heating at a temperature of about 50° C. to about 75° C.

13. The process of claim 10 , wherein about 3 equivalents of hydroxylamine and triethylamine are used per equivalent of compound of Formula III.

14. The process of claim 10 , wherein the compound of Formula III is obtained by reacting a compound of Formula IV with 4-(aminomethyl)benzonitrile hydrochloride under aprotic conditions, wherein the compound of Formula IV is:

15. The process of claim 14 , wherein the aprotic conditions comprise triethylamine in dichloromethane.

16. The process of claim 14 , wherein the aprotic conditions further comprise 1-propanephosphonic anhydride in ethyl acetate.

17. The process of claim 16 , wherein the aprotic conditions comprise incubating the compound of Formula IV with 4-(aminomethyl)benzonitrile hydrochloride and 1-propanephosphonic anhydride at a temperature of about 5° C. to about 39° C.

18. The process of claim 1 , wherein the compound of Formula I is selected from the group consisting of:

19. The process of claim 1 , wherein the compound of Formula I is 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide or a salt thereof.

20. The process of claim 19 , wherein the compound of Formula I is 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jul 1, 2022
From: SLR INVESTMENT CORP
To: REZOLUTE, INC.
Reel/Frame 060419/0315 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 15, 2021
From: REZOLUTE, INC.
To: SLR INVESTMENT CORP., AS COLLATERAL AGENT
Reel/Frame 055949/0730 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2020
From: SINHA, SUKANTO; CHILCOTE, TAMIE
To: ACTIVESITE PHARMACEUTICALS, INC.
Reel/Frame 053504/0527 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2020
From: KRISHNAN, BABURAJ; BHAT, GANAPATI; MALIK, VINEET
To: REZOLUTE, INC.
Reel/Frame 053396/0938 →
Continuity (2)
Provisional Application 62871526 · Jul 8, 2019
Related Publication 20210009526A1 · Jan 14, 2021